Take2 Health and KPMG Reached Partnership to Enlist the Take2 Prophecy™ as Employee Benefit
From 1 October 2021 onwards, KPMG employees could choose the Take2 Prophecy™ Test for Nasopharyngeal Cancer and be eligible for reimbursement under their employees’ medical check-up benefit.
This collaboration not only shows the multination corporations’ recognition for innovative medical technologies, but also stresses the emphasis on employees’ health, as well as the importance of early cancer detection.
In recent years, more and more businesses are creating considerate working environments and offering thoughtful benefits to attract talents, including providing a comprehensive medical check-up for employees and their families, as well as other health management related welfare. Take2 Health is pleased to work with businesses and to contribute to fulfilling employee’s needs by means of including early cancer detection in employee benefit schemes and raising awareness towards the importance of preventive healthcare.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
